Pharmaceuticals & Biotechnology | Pharma & Biotech Resources

Electronic submissions can substantially reduce submission time, allowing for a quicker release of products onto the market. However, the implementation and handling of eCTD can be problematic due to different standards at each European agency. In this interview Dr. Hannes

Pilar Carrero Director of Safety Medical Writing at Novo Nordisk, joins Andrea Charles from Pharma IQ, to discuss the impact social media has had on drug safety and risk managment and the dawn of a new era for pharmacovigilance. Carrero also shares her insights on optimising

Srdjan Capkun, Assistant Professor at the Swiss Federation Institute of Technology, joins Helen Winsor from Pharma IQ, to discuss securing access and reprogramming of medical devices. In this interview Capkun defines the problem of secure access and reprogramming of implantable

In this interview Helen Winsor from Pharma IQ, speaks to lyophilisation expert, Michael Pikal, Professor of Pharmaceutics at the University of Connecticut, who has dedicated his life’s work to freeze drying. Pikal sheds light on this complex field, explaining just

Celia Banks, R&D and Medical BT CI Lead at Pfizer, joins Helen Winsor from Pharma IQ, to discuss whether Lean innovation is the non sequitur it seems, or actually a real possibility. Banks offers some step-by-step pointers on how it can be embedded into R&D processes and

Chris Jennison, Professor of Statistics at the University of Bath, talks to Helen Winsor from Pharma IQ, about adaptive and group sequential clinical methods for clinical trial design and how important group sequential design is to clinical trials. Jennison also shares his

Effective partnerships can play a vital role in the drug discovery process and can contribute to an enhanced product pipeline and increased profitability. In this interview Richard Morphy from the Medicinal Chemistry Dept at the Schering-Plough Research Institute,

In this interview Jerold Martin, Sr. V.P., Global Scientific Affairs, Biopharmaceuticals, Pall Life Sciences and Chairman of the Board and Technology Committee at the BPSA, speaks to Andrea Charles from Pharma IQ, about future trends for Single-Use biomanufacturing and the

Peter Schroeer, Director Europe, Quality Systems & Regulatory Affairs at Johnson & Johnson, speaks to Andrea Charles from Pharma IQ, about the current  compliance challenges the medical device market faces and what impact the reuse warning statement

The epidemiology of increasing resistance problem continues to garner much attention. A bacteria capable of opposing the inhibitory (bacteriostatic) or killing (bacteriocidal) effects of antibiotics has unfortunately become an increasingly common occurrence and presents a serious threat

Steven A. Jacobs, President, Global BioPharm Solutions, shares his insights with Andrea Charles from Pharma IQ, about the paradigm shift in pharma and how this will this directly affect the clinical trial supply area. Jacobs also speaks about the movement of clinical trial

Cornelius Pompe, Head of Freeze Dried Product Development at LFB Technologies, speaks to Andrea Charles from Pharma IQ, about the key drivers of the lyophilisation market and shares his insights on how advances in freeze drying have impacted on formulation development. Pompe

Public awareness of biobanking is growing and lack of transparency can lead to closure of a biobanking project. David Kaufman, Director of Research and Statistics Genetics and Public Policy Center, John Hopkins University, speaks to Andrea Charles from Pharma IQ, about

Contaminations in biological products in 2009 and the porcine circovirus contamination of GSK’s Rotarix vaccine in March of this year has highlighted the issue of viral safety in biologics more than ever before. Marc Martin, Viral Safety Assessor at AFSSAPS, joins Helen Winsor from

Paul Wiberg-Jørgensen, VP Logistics, Statens Serum Institut, speaks with Andrea Charles from Pharma IQ, about recent European supply chain trends and how the landscape is evolving to meet the needs of the pharmaceutical industry.  In this interview Wiberg-Jørgensen,